Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
Eribulin is the promising agent for late-line metastatic breast cancer patients. The aim of
this Phase II, double-arm, open-label and prospective clinical trial is to assess the
efficacy and safety of Eribullin or Eribulin combined with Anlotinib in patients with
metastatic breast cancer